Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

被引：0
|
作者：
Matasar, Matthew J.
Haioun, Corinne
Sancho, Juan-Manuel
Viardot, Andreas
Izquierdo, Antonia Rodriguez
Martin, Eva Maria Donato
Garcia-Sancho, Alejandro Martin
Sandoval-Sus, Jose David
Tilly, Herve
Vandenberghe, Elizabeth
Hirata, Jamie
Choudhry, Priya
Chang, Yi Meng
Musick, Lisa
McMillan, Andrew
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Grp Hosp Henri Mondor, Lymphoid Malignancies Unit, Creteil, France
[3] ICO HU Germans Trias I Pujol, Barcelona, Spain
[4] Univ Hosp Ulm, Ulm, Germany
[5] Hosp Univ 12 Octubre, Serv Hemat, Madrid, Spain
[6] Hosp Univ Dr Peset Serv Hematol, Salamanca, Spain
[7] Hosp Clin Univ Salamanca, Serv Hematol, Salamanca, Spain
[8] Mem Healthcare Inst, Moffitt Canc Ctr, Pembroke Pines, FL USA
[9] Ctr Henri Becquerel, Dept Hematol, Rouen, France
[10] Ctr Henri Becquerel, U1245, Rouen, France
[11] Univ Rouen, Rouen, France
[12] St James Hosp Canc Clin Trials Off, Dublin, Ireland
[13] Genentech Inc, South San Francisco, CA USA
[14] F Hoffmann La Roche Ltd, Mississauga, ON, Canada
[15] Nottingham Univ Hosp NHS Trust, Ctr Clin Haematol, Nottingham, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7551
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study
    Sehn, Laurie H.
    Herrera, Alex F.
    Matasar, Matthew J.
    Kamdar, Manali
    McMillan, Andrew K.
    Kim, Tae Min
    Kim, Won Seog
    Hertzberg, Mark
    Ozcan, Muhit
    Penuel, Elicia
    Cheng, Ji
    Hirata, Jamie M.
    Ku, Grace
    Flowers, Christopher
    BLOOD, 2017, 130
  • [42] Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol
    Eslami, Mohammadreza
    Mehrabi, Mahdi
    Payandeh, Mehrdad
    Saba, Fakhredin
    PLOS ONE, 2024, 19 (08):
  • [43] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Gatwood, Justin
    Masaquel, Anthony
    Ross, Ryan
    Sheinson, Danny
    Hossain, Farah
    Li, Jia
    James, Cameron
    Fox, David
    BLOOD, 2022, 140 : 7906 - 7907
  • [44] First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
    Zhang, Huilai
    Cheng, Ying
    Yang, Haiyan
    Zhang, Liling
    Zou, Liqun
    Guo, Ye
    Cao, Junning
    Huang, Huiqiang
    Wang, Zhao
    Huang, Sha
    Liang, Zhiyu
    Lyu, Jiaoyan
    Fang, Yiqian
    Cohen, Aileen
    Zhou, Keshu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL): results of the phase III POLARIX study
    Dietrich, S.
    Tilly, H.
    Morschhauser, F.
    Sehn, L. H.
    Friedberg, J.
    Trneny, M.
    Sharman, J. P.
    Herbaux, C.
    Burke, J. M.
    Matasar, M.
    Rai, S.
    Izutsu, K.
    Mehta-Shah, N.
    Oberic, L.
    Chauchet, A.
    Jurczak, W.
    Song, Y.
    Greil, R.
    Mykhalska, L.
    Burgues, J. M. B.
    Cheung, M. C.
    Pinto, A.
    Shin, H-J
    Hapgood, G.
    Munhoz, E.
    Abrisqueta, P.
    Gau, J-P
    Hirata, J.
    Jiang, Y.
    Yan, M.
    Lee, C.
    Flowers, C.
    Salles, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 193 - 194
  • [46] Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
    Arcari, Annalisa
    Chiappella, Annalisa
    Valenti, Vanessa
    Zanlari, Luca
    Tani, Monica
    Marasca, Roberto
    Cabras, Maria Giuseppina
    Spina, Michele
    Santagostino, Alberto
    Ilariucci, Fiorella
    Carli, Giuseppe
    Musto, Pellegrino
    Savini, Paolo
    Marino, Dario
    Ghio, Francesco
    Gentile, Massimo
    Cox, Maria Christina
    Della Seta, Roberta
    Vallisa, Daniele
    BLOOD, 2014, 124 (21)
  • [47] Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
    F. Felizzi
    Aino Launonen
    P.-O. Thuresson
    PharmacoEconomics - Open, 2023, 7 : 37 - 46
  • [48] Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.
    Bartlett, Nancy L.
    Yasenchak, Christopher A.
    Ashraf, Khaleel K.
    Harwin, William N.
    Orcutt, James Michael
    Kuriakose, Philip
    Zinzani, Pier Luigi
    Mamidipalli, Adrija
    Fenton, Keenan
    Glenn, Consuelo
    Nowakowski, Grzegorz S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Trial-in-Progress: Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Bartlett, Nancy L.
    Yasenchak, Christopher A.
    Sims, Robert B.
    Nowakowski, Grzegorz S.
    BLOOD, 2020, 136
  • [50] A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage
    Toubai, Tomomi
    Kuroda, Junya
    Suehiro, Youko
    Mishima, Yuko
    Sunami, Kazutaka
    Kato, Koji
    Uoshima, Nobuhiko
    Kumode, Takahiro
    Ota, Ai
    Mitsuki, Kaori
    Yokota, Daisuke
    Sano, Yuri
    Terui, Yasuhito
    BLOOD, 2023, 142
12345